| Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors M Xiao, H Yang, W Xu, S Ma, H Lin, H Zhu, L Liu, Y Liu, C Yang, Y Xu, ... Genes & development 26 (12), 1326-1338, 2012 | 1115 | 2012 |
| The Hippo pathway: biology and pathophysiology S Ma, Z Meng, R Chen, KL Guan Annual review of biochemistry 88 (1), 577-604, 2019 | 870 | 2019 |
| Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation H Yang, Y Liu, F Bai, JY Zhang, SH Ma, J Liu, ZD Xu, HG Zhu, ZQ Ling, ... Oncogene 32 (5), 663-669, 2013 | 650 | 2013 |
| WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferation Y Wang, M Xiao, X Chen, L Chen, Y Xu, L Lv, P Wang, H Yang, S Ma, ... Molecular cell 57 (4), 662-673, 2015 | 311 | 2015 |
| The Hippo pathway effector proteins YAP and TAZ have both distinct and overlapping functions in the cell SW Plouffe, KC Lin, JL Moore, FE Tan, S Ma, Z Ye, Y Qiu, B Ren, KL Guan Journal of Biological Chemistry 293 (28), 11230-11240, 2018 | 227 | 2018 |
| Oncometabolite D-2-hydroxyglutarate inhibits ALKBH DNA repair enzymes and sensitizes IDH mutant cells to alkylating agents P Wang, J Wu, S Ma, L Zhang, J Yao, KA Hoadley, MD Wilkerson, ... Cell reports 13 (11), 2353-2361, 2015 | 217 | 2015 |
| Dual-phase stimulated Raman scattering microscopy for real-time two-color imaging R He, Y Xu, L Zhang, S Ma, X Wang, D Ye, M Ji Optica 4 (1), 44-47, 2017 | 108 | 2017 |
| R-2-hydroxyglutarate as the key effector of IDH mutations promoting oncogenesis D Ye, S Ma, Y Xiong, KL Guan Cancer cell 23 (3), 274-276, 2013 | 102 | 2013 |
| STRIPAK integrates upstream signals to initiate the Hippo kinase cascade R Chen, R Xie, Z Meng, S Ma, KL Guan Nature cell biology 21 (12), 1565-1577, 2019 | 97 | 2019 |
| Oncogenic R132 IDH1 mutations limit NADPH for de novo lipogenesis through (D) 2-hydroxyglutarate production in fibrosarcoma cells MG Badur, T Muthusamy, SJ Parker, S Ma, SK McBrayer, T Cordes, ... Cell reports 25 (4), 1018-1026. e4, 2018 | 85 | 2018 |
| Transcriptional repression of estrogen receptor alpha by YAP reveals the Hippo pathway as therapeutic target for ER+ breast cancer S Ma, T Tang, G Probst, A Konradi, C Jin, F Li, JS Gutkind, XD Fu, ... Nature communications 13 (1), 1061, 2022 | 68 | 2022 |
| D-2-hydroxyglutarate is essential for maintaining oncogenic property of mutant IDH-containing cancer cells but dispensable for cell growth S Ma, B Jiang, W Deng, ZK Gu, FZ Wu, T Li, Y Xia, H Yang, D Ye, Y Xiong, ... Oncotarget 6 (11), 8606, 2015 | 65 | 2015 |
| Hippo signalling maintains ER expression and ER+ breast cancer growth S Ma, Z Wu, F Yang, J Zhang, RL Johnson, MG Rosenfeld, KL Guan Nature 591 (7848), E1-E10, 2021 | 40 | 2021 |
| L2hgdh deficiency accumulates l-2-hydroxyglutarate with progressive leukoencephalopathy and neurodegeneration S Ma, R Sun, B Jiang, J Gao, W Deng, P Liu, R He, J Cui, M Ji, W Yi, ... Molecular and cellular biology, 2017 | 38 | 2017 |
| Polycystic kidney disease: a Hippo connection S Ma, KL Guan Genes & Development 32 (11-12), 737-739, 2018 | 23 | 2018 |
| YAP silencing by RB1 mutation is essential for small-cell lung cancer metastasis Z Wu, J Su, F Li, T Chen, J Mayner, A Engler, S Ma, Q Li, KL Guan Nature Communications 14 (1), 5916, 2023 | 8 | 2023 |
| D-2-hydroxyglutarate is essential for maintaining oncogenic property of mutant IDH S Ma, B Jiang, W Deng Oncotarget, 6 (11), 2015 | | 2015 |
